Brian Michael Olson, PhD

Instructor, Hematology & Medical Oncology, Urology and Surgery

Emory University School of Medicine

Office: Winship Cancer Institute of Emory Unviersity

Phone: (404) 778-4767

Email: brian.olson@emory.edu

Biography

Dr. Olson is an instructor in the Division of Basic and Translational Science of the Department of Hematology and Medical Oncology at Emory Unicersity School of Medicine. He holds joint appointments in the Department of Urology and the Department of Surgery. Prior to arriving at Emory, he was a staff scientist at University of Chicago in Illinois.

Dr. Olson obtained his PhD in Cancer Biology from University of Wisconsin in Madison, Wisconsin, where he also completed his post-doctoral fellowship.

He is an active member of several professional societies including Society for Immunotherapy of Cancer, American Association for Cancer Research, and American Association of Immunologists.

Research

Dr. Olson's research focuses on identifying rational combinatorial treatment strategies to enhance the efficacy of immunotherapy for the treatment of cancer, and evaluating these approaches in pre-clinical studies and early-stage clinical trials.  He led preclinical and translational research projects developing a vaccine for the treatment of prostate cancer, which he translated into a clinical trial in patients with metastatic prostate cancer. In the process, he identified tumor escape mechanisms to this vaccination approach, as well as escape mechanisms to approved therapies for prostate cancer, that have led to combinatorial strategies that are being evaluated in phase I clinical trials.

Dr. Olson's research has also focused on identifying specific genomic alterations that cause tumors to become less responsive to immunotherapy, and evaluating targeted therapeutic approaches to counteract these alterations and enhance the efficacy of immunotherapy. Throughout these studies, he has focused on a bench-to-bedside-to-bench translational research approach: taking results from the laboratory and moving them into early-stage clinical trials, and then taking the results of these clinical trials and bringing them back to the lab to inform the next generation of clinical trials.

Publications